XML 42 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Segment Information (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended
Jul. 31, 2013
Jul. 31, 2012
Net revenue $ 3,020 $ 2,106
Sales and marketing costs (642) (709)
Stock- based compensation expense (552) (739)
Personalized Oncology Solutions [Member]
    
Net revenue 622 918
Direct cost of services (744) (717)
Sales and marketing costs (333) (435)
Other operating expenses 0 0
Stock- based compensation expense 0 [1] 0 [1]
Segment profit (loss) (456) (234)
Translational Oncology Solutions [Member]
    
Net revenue 2,398 1,188
Direct cost of services (872) (691)
Sales and marketing costs (246) (192)
Other operating expenses (389) (363)
Stock- based compensation expense 0 [1] 0 [1]
Segment profit (loss) 891 (58)
Unallocated Corporate Overhead [Member]
    
Net revenue 0 0
Direct cost of services 0 0
Sales and marketing costs 0 0
Other operating expenses (652) (568)
Stock- based compensation expense (552) [1] (739) [1]
Segment profit (loss) (1,204) (1,307)
Consolidated [Member]
    
Net revenue 3,020 2,106
Direct cost of services (1,614) (1,408)
Sales and marketing costs (579) (627)
Other operating expenses (1,041) (931)
Stock- based compensation expense (552) [1] (739) [1]
Segment profit (loss) $ (766) $ (1,599)
[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.